Table 5.
ORs (95% CIs) of thyroid disease for IQR shift in PFAA concentrations in children 1–17 years of age, Mid-Ohio Valley, 2005–2006.
| Reported | Subclinical | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thyroid disease | Hypothyroidism | Hypothyroidisma | Hyperthyroidisma | |||||||||||||
| PFAA | n | OR (95% CI) | n | OR (95% CI) | n | OR (95% CI) | n | OR (95% CI) | ||||||||
| Modeled in utero PFOA | 27 | 1.47 (0.95, 2.27) | 20 | 1.61 (0.96, 2. 63) | 155 | 0.94 (0.76, 1.16) | 31 | 1.10 (0. 69, 1.74) | ||||||||
| Measured serum PFOA | 61 | 1.44 (1.02, 2.03) | 39 | 1.54 (1.00, 2.37) | 365 | 0.98 (0.86, 1.15) | 78 | 0.81 (0.58, 1.15) | ||||||||
| Measured serum PFOS | 61 | 0.8 (0.62, 1.08) | 39 | 0.91 (0.63, 1,31) | 365 | 0.99 (0.86, 1.13) | 78 | 0.80 (0.62, 1.02) | ||||||||
| Measured serum PFNA | 61 | 1.05 (0.78, 1.41) | 39 | 1.11 (0.77, 1.60) | 365 | 0.99 (0.88, 1.12) | 78 | 0.78 (0.61, 1.01) | ||||||||
| PFAAs were natural log-transformed. Models were adjusted by age and sex. aBased on hormonal levels at survey after excluding people who self-reported thyroid disease and/or thyroid medication. | ||||||||||||||||